Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEY1107 + temozolomide
- Development stage
- Phase 1
- Lead developer
- BeyondBio
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**BEY1107 + temozolomide** is an experimental combination therapy being investigated primarily for glioblastoma multiforme. BEY1107 (also known as Avotaciclib) is a selective small molecule inhibitor of cyclin-dependent kinase 1 (CDK1), resulting in G2/M cell cycle arrest, apoptosis, and suppression of cancer stem cell renewal. Temozolomide is an alkylating agent that induces cell death by methylating DNA at the O6 and N7 positions of guanine, leading to DNA damage and apoptosis. The combination is designed to enhance therapeutic efficacy and potentially overcome resistance to standard cytotoxic chemotherapy. Clinical development is ongoing in phase 1 trials for recurrent or progressive glioblastoma multiforme.
- Brand names
- TemodalTemomedac
- Other names
- BEY1107 + temozolomide
02
Targets
CDK1 (Cyclin-dependent kinase 1)DNA
Beyond the preview
Go deeper on BEY1107 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEY1107 + temozolomide.